3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT
Astrid Gosewisch,Harun Ilhan,Sebastian Tattenberg,Andrea Mairani,Katia Parodi,Julia Brosch,Lena Kaiser,Franz Josef Gildehaus,Andrei Todica,Sibylle Ziegler,Peter Bartenstein,Guido Böning
DOI: https://doi.org/10.1186/s13550-019-0548-z
IF: 3.434
2019-08-14
EJNMMI Research
Abstract:<h3 class="Heading">Background</h3><p class="Para">The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on <em class="EmphasisTypeItalic">S</em> values, which are pre-computed for reference anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate the potential value of image-based BM localization.</p><p class="Para">This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177 whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of bone lesions (MC2). Results were compared with those from <em class="EmphasisTypeItalic">S</em> values (SMIRD). BM absorbed doses were correlated with the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization.</p><h3 class="Heading">Results</h3><p class="Para">Median BM absorbed doses were 130, 37, and 11 mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: <em class="EmphasisTypeItalic">r</em> = − 0.63, <em class="EmphasisTypeItalic">p</em> = 0.04; MC2: r = − 0.71, <em class="EmphasisTypeItalic">p</em> = 0.01; SMIRD: <em class="EmphasisTypeItalic">r</em> = − 0.62, <em class="EmphasisTypeItalic">p</em> = 0.04). For both investigated patients, BM localization via Tc-99m-anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1.</p><h3 class="Heading">Conclusion</h3><p class="Para">Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and future studies are recommended to support an improvement for the prediction of hematoxicities.</p>
radiology, nuclear medicine & medical imaging